J Korean Med Sci.  2004 Dec;19(6):815-819. 10.3346/jkms.2004.19.6.815.

De novo CD5 Positive Diffuse Large B-cell Lymphomas with Bone Marrow Involvement in Korean

• Kong SY
• Cho EH
• Woo HY
• Park Q
• Ko YH
• Kim SH

• KMID: 1778562
• DOI: http://doi.org/10.3346/jkms.2004.19.6.815

Abstract

In CD5 positive (CD5+) mature B-cell lymphomas, newly recognized CD5+ diffuse large B-cell lymphoma (DLBCL) has been characterized by aggressive features. We studied twenty-five cases with CD5+ lymphomas involving bone marrow. Eleven cases were diagnosed as chronic lymphocytic leukemia, six cases were diagnosed as mantle cell lymphoma (MCL), and three cases with morphologic characteristics of MCL and without both the cyclin D1 expression and IGH/CCND1 rearrangement were unclassifiable. The remaining five cases, showing large to medium-sized lym-phoid cells with prominent nucleoli and a moderate amount of cytoplasm, were diagnosed as DLBCL. Five DLBCL cases were positive for CD5, CD20, surface immuno-globulin, but negative for CD23. Patients with CD5+ DLBCL showed a high age of onset (median, 68 yr) and two patients expired one month after the diagnosis. Since CD5+ DLBCL forms a distinct subgroup of DLBCL, a study of CD5 expression in DLBCL would be helpful to predict prognosis and to determine future therapeutic strategy. To the best of our knowledge, this is the first report on de novo CD5+ DLBCL in Koreans.

Keyword

Antigens, CD5; Leukemia, Lymphocytic, Chronic; Lymphoma, Mantle-Cell; Lymphoma, Large-Cell, Diffuse

MeSH Terms

Aged
Antigens, CD5/*metabolism
Bone Marrow Neoplasms/*epidemiology/*metabolism
Female
Humans
Korea/epidemiology
Lymphoma, B-Cell/*metabolism
Lymphoma, Large-Cell, Diffuse/*epidemiology/*metabolism
Male
Middle Aged
Risk Assessment/methods
Risk Factors
Tumor Markers, Biological/*metabolism

Figure

• 

  Fig. 1 The morphologic findings of a case with CD5+ diffuse large B-cell lymphomas. Medium sized cells with moderately condensed cleaved nuclei with distinct nucleoli, and a moderate amount of cytoplasm are observed. (A) Bone marrow aspirate, ×1,000, Wright-Giemsa stain, (B) Bone marrow biopsy, ×400 Hematoxylin-Eosin stain.

• 

  Fig. 2 Immunophenotyping of malignant lymphoid cells of CD5 positive diffuse large B-cell lymphomas shows CD5+CD10-CD 19+CD20+CD23- phenotype. (A) CD45/SSC (B) CD5/20 (C) CD 10/19 (D) CD3/23, Note the gated areas, black head arrowed.

Reference

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2000. 1:53–66.

2. Ko YH, Kim CW, Park CS, Jang HK, Lee SS, Kim SH, Ree HJ, Lee JD, Kim SW, Huh JR. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer. 1998. 83:806–812.

3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998. 16:2780–2795.

4. Yamaguchi M, Ohno T, Oka K, Taniguchi M, Ito M, Kita K, Shiku H. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999. 105:1133–1139.

5. Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, Suzumiya J, Murase T, Miura I, Akasaka T, Tamaru J, Suzuki R, Kagami Y, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002. 99:815–821.

6. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995. 147:207–216.

7. Pileri SA, Dirnhofer S, Went P, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology. 2002. 41:482–509.

8. Katzenberger T, Lohr A, Schwarz S, Dreyling M, Schoof J, Nickenig C, Stilgenbauer S, Kalla J, Ott MM, Muller-Hermelink HK, Ott G. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood. 2003. 101:699–702.

9. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003. 101:78–84.

10. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001. 13:325–334.

11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999. 17:3835–3849.

12. Mitelman F. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger.

13. Cro L, Guffanti A, Colombi M, Cesana B, Grimoldi MG, Patriarca C, Goldaniga M, Neri A, Intini D, Cortelezzi A, Maiolo AT, Baldini L. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias. Leukemia. 2003. 17:125–132.

14. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002. 8:68–74.

15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, Le-Blanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002. 346:1937–1947.

16. Pospisil R, Fitts MG, Mage RG. CD5 is a potential selecting ligand for B cell surface immunoglobulin framework region sequences. J Exp Med. 1996. 184:1279–1284.

17. Kobayashi T, Yamaguchi M, Kim S, Morikawa J, Ogawa S, Ueno S, Suh E, Dougherty E, Shmulevich I, Shiku H, Zhang W. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res. 2003. 63:60–66.

18. Yin Z, Giacomello E, Gabriele E, Zardi L, Aota S, Yamada KM, Skerlavaji B, Doliana R, Colombatti A, Perris R. Cooperative activity of alpha4beta1 and alpha4beta7 integrins in mediating human B-cell lymphoma adhesion and chemotaxis on fibronectin through recognition of multiple synergizing binding sites within the central cell-binding domain. Blood. 1999. 93:1221–1230.

19. Terol MJ, Lopez-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol. 1999. 17:1869–1875.

20. Corcoran LM, Karvelas M, Nossal GJ, Ye ZS, Jacks T, Baltimore D. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev. 1993. 7:570–582.

21. Rutella S, Rumi C, Di Mario A, Leone G. Expression of thrombospondin receptor (CD36) in chronic B-cell lymphoproliferative disorders: a role in tumor metastasis? Eur J Histochem. 1997. 41:Suppl 2. (2):53–54.